Get the latest news, insights, and market updates on CODX (Co-Diagnostics, Inc.). Explore the news page 1 on MyTopStock.com for investor discussions, analysis, and real-time stock performance coverage.
Co-Diagnostics Initiates Clinical Evaluations for Upper Respiratory Multiplex Point-of-Care Test on Co-Dx™ PCR Platform to Support Submission to the U.S. FDA
Co-Diagnostics, Inc. (Nasdaq: CODX) (the "Company" or "Co-Dx"), a molecular diagnostics company with a unique, patented platform for the development of molecular diagnostic tests, today announced that it has begun clinical evaluations for its Co-Dx™ PCR Flu A/B, COVID-19, RSV Test Kit. The clinical performance testing is expected to support a submission to the United States Food and Drug Administration ("FDA") for 510(k) clearance of the upper respiratory multiplex point-of-care test, and the Co Nov 18, 2025 - $CODX
Co-Diagnostics Reports Third Quarter 2025 Financial Results
Co-Diagnostics, Inc. (NASDAQ: CODX) ("Co-Diagnostics," "Co-Dx," or "the Company"), a molecular diagnostics company with a unique, patented platform for the development of molecular diagnostic tests, today announced its financial results for the third quarter ended September 30, 2025. Nov 13, 2025 - $CODX
Co-Diagnostics (CODX) Q3 2025 Earnings Transcript
Earlier today, Co-Diagnostics released financial results from the third quarter ended 09/30/2025. In addition to diagnostic test developments and timing for commencement of clinical evaluations, this includes statements concerning the company's KodiX PCR testing platform, which requires regulatory approval and marketing authorization for diagnostic use and is not currently for sale. Nov 13, 2025 - $CODX
Progyny (PGNY) Q3 Earnings and Revenues Beat Estimates
Progyny (PGNY) delivered earnings and revenue surprises of +15.38% and +4.19%, respectively, for the quarter ended September 2025. Do the numbers hold clues to what lies ahead for the stock? Nov 6, 2025 - $CODX
Co-Diagnostics Engages Maxim Group to Pursue SPAC Transaction for its Indian Joint Venture, CoSara Diagnostics Pvt. Ltd
Co-Diagnostics, Inc. (Nasdaq: CODX) (the "Company" or "Co-Dx"), a molecular diagnostics company with a patented platform for developing advanced molecular diagnostic tests, today announced that it has engaged Maxim Group LLC ("Maxim") as its exclusive financial advisor to assist the Company in identifying potential strategic alternatives for the Company's Indian joint venture, CoSara Diagnostics Pvt. Ltd. ("CoSara"), including a merger with a Special Purpose Acquisition Company ("SPAC") or simil Nov 5, 2025 - $CODX
CareDx (CDNA) Surpasses Q3 Earnings and Revenue Estimates
CareDx (CDNA) delivered earnings and revenue surprises of +115.38% and +5.07%, respectively, for the quarter ended September 2025. Do the numbers hold clues to what lies ahead for the stock? Nov 4, 2025 - $CODX
Co-Diagnostics to Integrate and Implement Proprietary Artificial Intelligence Technology into Co-Dx™ Primer Ai™ Platform
Co-Diagnostics, Inc. (Nasdaq: CODX) (the "Company" or "Co-Dx"), a molecular diagnostics company with a unique, patented platform for the development of molecular diagnostic tests, today announced the formation of a newly organized, artificial intelligence ("AI") business unit, led by Chief Technology & AI Officer Christopher Thurston, to integrate the Company's existing and planned AI applications into the Co-Dx™ Primer Ai™ platform. Nov 3, 2025 - $CODX
We use cookies and similar technologies to collect and process data such as browsing activity or unique identifiers.
Selecting "Allow All" lets us enhance your experience and provide personalized content and ads.
Choosing "Essential Cookies Only" enables only the cookies necessary for core site functions, such as staying logged in.
For more information, please see our Privacy Policy.
Continue with Google
Continue with Facebook
Continue with Microsoft
Continue with Apple